EUVIMEDEUVIMED entdecken
Crossref

Gefitinib as an antimalarial: unveiling its therapeutic potential

Varun Gorki, Neha Sylvia Walter, Monika Chauhan, Neelima Dhingra, Upma Bagai, Sukhbir Kaur

Inflammopharmacology · 2025

DOI: 10.1007/s10787-025-01682-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammopharmacology, 2025. Verfasst von Varun Gorki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India. Hauptthemen laut MEDLINE: Antimalarials, Gefitinib, Malaria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: University Grants Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistant strains of Plasmodium spp. pose a great threat to healthcare. Drug repurposing is a smart, and an effective way to look for new alternatives for different ailments including malaria. Protein tyrosine kinases (PTKs) play a crucial role in growth, maturation as well as differentiation of Plasmodium and this study explores antimalarial activity of PTKs inhibitor gefitinib using in silico and experimental approaches. The drug showed considerable inhibitory activity against P. falciparum 3D7 (IC50 0.49 µg/mL) and RKL-9 (IC50 0.83 µg/mL) strains. Isobologram analysis revealed substantial synergism between gefitinib and artesunate. Gefitinib illustrated highest negative D-score towards phosphoethanolamine methyltransferase followed by PfPK5 and CDPK1. Its acute toxicity was 4 g/kg. Gefitinib (100 mg/kg) exhibited a dose-dependent curative activity against P. berghei with 91.09% chemo-suppression and the combination of gefitinib 100 mg/kg and AS 50 mg/kg exhibited complete parasite clearance with no recrudescence which was also evidenced by cytokine analysis, biochemical as well as histopathological studies. At length, gefitinib illustrated considerable antiplasmodial action by targeting phosphoethanolamine methyltransferase, PfPK5 and CDPK1. The combination of gefitinib (100 mg/kg) and AS (50 mg/kg) holds promise for malaria treatment. Further, research is being done to evaluate its pharmacokinetic properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsGefitinibMalariaAnimalsPlasmodium falciparumMicePlasmodium bergheiDose-Response Relationship, DrugArtesunateDrug SynergismProtein Kinase InhibitorsHumansDrug Repositioning

Stichwörter der Autor:innen

PlasmodiumAntimalarial activityGefitinibMalariaTyrosine kinase inhibitors

Substanzen

AntimalarialsGefitinibArtesunateProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India.
  • Department of Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
  • Department of Biophysics, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
  • University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, 160014, India.
  • Parasitology Laboratory, Department of Zoology, Panjab University, Chandigarh, 160014, India. sukhbir@pu.ac.in.

Förderung

  • University Grants Commission

Zitieren

APA

Gorki, V., Walter, N. S., Chauhan, M., Dhingra, N., Bagai, U., & Kaur, S. (2025). Gefitinib as an antimalarial: unveiling its therapeutic potential. Inflammopharmacology. https://doi.org/10.1007/s10787-025-01682-5

Vancouver

Gorki V, Walter NS, Chauhan M, Dhingra N, Bagai U, Kaur S. Gefitinib as an antimalarial: unveiling its therapeutic potential. Inflammopharmacology. 2025. doi:10.1007/s10787-025-01682-5

BibTeX
@article{Gorki2025,
  author = {Gorki, Varun and Walter, Neha Sylvia and Chauhan, Monika and Dhingra, Neelima and Bagai, Upma and Kaur, Sukhbir},
  title = {Gefitinib as an antimalarial: unveiling its therapeutic potential},
  journal = {Inflammopharmacology},
  year = {2025},
  doi = {10.1007/s10787-025-01682-5}
}
Kostenlos starten →